Cost-effectiveness analysis of biological drugs in treating moderate to severe plaque psoriasis from the perspective of a health service provider

Republic in 2021, a cost-effectiveness analysis (CEA) was performed for the selected efficacy parameter of PASI 100. The analysis was performed and processed in an interactive way in Excel software into a graphical form, particularly in the form of forest plot graphs (in CER and ICER parameters) and a two-dimensional graph (cost vs. effectiveness) with effectiveness lines being indicated. Results: There are as much as several-fold differences in the cost-effectiveness of individual products according to the CER and ICER parameter values. When taking into account 95% confidence intervals, some differences between the products are even statistically significant. In the case of the most cost-effective sequence of treatment to a gradually more effective drug in a single patient during the induction phase of treatment, induction treatment with a less effective biological drug can be newly initiated, based on such cost savings, in two more patients than when using the second most cost-effective sequence of treatment escalation. Conclusion: A cost-effectiveness analysis (CEA) of biological drugs for the treatment of psoriasis at the level of a health service provider has great potential in the effort to maximize the effectiveness of treatment with limited financial resources or in the effort to provide, with the same limitations, effective treatment to additional patients.